Carcinoembryonic antigen interacts with TGF-β receptor and inhibits TGF-β signaling in colorectal cancers

Cancer Research

Volumn 70, Issue 20, 2010, Pages 8159-8168

  Li, Ying ^a   Cao, Hong ^a   Jiao, Zhongxian ^a   Pakala, Suresh B ^b   Sirigiri, Divijendra Natha Reddy ^b   Li, Wenpin ^a   Kumar, Rakesh ^b   Mishra, Lopa ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIVER METASTASIS; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

CARCINOEMBRYONIC ANTIGEN; CELL DIVISION; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA PRIMERS; GENES, MYC; HUMANS; MICROSATELLITE REPEATS; MICROSCOPY, CONFOCAL; NEOPLASM METASTASIS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 78049300012     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1073     Document Type: Article

References (47)

1. Nollau P, Scheller H, Kona-Horstmann M, et al. Expression of CD66a (human C-CAM) and other members of the carcinoembryonic antigen gene family of adhesion molecules in human colorectal adenomas. Cancer Res 1997;57:2354-7.
2. Rosenberg M, Nedellec P, Jothy S, Fleiszer D, Turbide C, Beauchemin N. The expression of mouse biliary glycoprotein, a carcinoembryonic antigen-related gene, is down-regulated in malignant mouse tissues. Cancer Res 1993;53:4938-45.
3. Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 1989;57:327-34.
4. Oikawa S, Inuzuka C, Kuroki M, Matsuoka Y, Kosaki G, Nakazato H. Cell adhesion activity of non-specific cross-reacting antigen (NCA) and carcinoembryonic antigen (CEA) expressed on CHO cell surface: homophilic and heterophilic adhesion. Biochem Biophys Res Commun 1989;164:39-45.
5. Stanners CP, Fuks A. Properties of adhesion mediated by the human CEA family. In: Bast RC, Jr., Ravdin P. Cell adhesion and communication mediated by the CEA family: basic and clinical perspectives: Chapter 3; 1998. p. 57-71.
6. Bast RC, Jr., Ravdin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-78.
7. Henson DE, Fielding LP, Grignon DJ, et al, Members of the Cancer Committee. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Summary. Arch Pathol Lab Med 1995;119:1109-12.
8. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells. Oncogene 2004;23:465-73. (Pubitemid 38175001)
9. Eidelman FJ, Fuks A, DeMarte L, Taheri M, Stanners CP. Human carcinoembryonic antigen, an intercellular adhesion molecule, blocks fusion and differentiation of rat myoblasts. J Cell Biol 1993;123:467-75. (Pubitemid 23313969)
10. Ordonez C, Screaton RA, Ilantzis C, Stanners CP. Human carcinoembryonic antigen functions as a general inhibitor of anoikis. Cancer Res 2000;60:3419-24. (Pubitemid 30482158)
11. Screaton RA, DeMarte L, Draber P, Stanners CP. The specificity for the differentiation blocking activity of carcinoembryonic antigen resides in its glycophosphatidyl-inositol anchor. J Cell Biol 2000;150:613-26.
12. Soeth E, Wirth T, List HJ, et al. Controlled ribozyme targeting demonstrates an antiapoptotic effect of carcinoembryonic antigen in HT29 colon cancer cells. Clin Cancer Res 2001;7:2022-30. (Pubitemid 32994841)
13. Taheri M, Saragovi HU, Stanners CP. The adhesion and differentiation- inhibitory activities of the immunoglobulin superfamily member, carcinoembryonic antigen, can be independently blocked. J Biol Chem 2003;278:14632-9. (Pubitemid 36799785)
14. Blumenthal RD, Osorio L, Hayes MK, Horak ID, Hansen HJ, Goldenberg DM. Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft. Cancer Immunol Immunother 2005;54:315-27. (Pubitemid 40238925)
15. Hostetter RB, Augustus LB, Mankarious R, et al. Carcinoembryonic antigen as a selective enhancer of colorectal cancer metastasis. J Natl Cancer Inst 1990;82:380-5. (Pubitemid 20108028)
16. Thomas P, Gangopadhyay A, Steele G, Jr., et al. The effect of transfection of the CEA gene on the metastatic behavior of the human colorectal cancer cell line MIP-101. Cancer Lett 1995;92:59-66.
17. Samara RN, Laguinge LM, Jessup JM. Carcinoembryonic antigen inhibits anoikis in colorectal carcinoma cells by interfering with TRAILR2 (DR5) signaling. Cancer Res 2007;67:4774-82.
18. Screaton RA, Penn LZ, Stanners CP. Carcinoembryonic antigen, a human tumor marker, cooperates with Myc and Bcl-2 in cellular transformation. J Cell Biol 1997;137:939-52.
19. Camacho-Leal P, Stanners CP. The human carcinoembryonic antigen (CEA) GPI anchor mediates anoikis inhibition by inactivation of the intrinsic death pathway. Oncogene 2008;27:1545-53. (Pubitemid 351347873)
20. Massague J, Blain SW, Lo RS. TGFβ signaling in growth control, cancer, and heritable disorders. Cell 2000;103:295-309.
21. Mishra L, Shetty K, Tang Y, Stuart A, Byers SW. The role of TGF-β and Wnt signaling in gastrointestinal stem cells and cancer. Oncogene 2005;24:5775-89.
22. Akhurst RJ. TGF β signaling in health and disease. Nat Genet 2004;36:790-2.
23. Shi Y, Massague J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 2003;113:685-700.
24. Massague J. TGF-β in cancer. Cell 2008;134:215-30.
25. Tang Y, Katuri V, Dillner A, Mishra B, Deng CX, Mishra L. Disruption of transforming growth factor-β signaling in ELF β-spectrin-deficient mice. Science 2003;299:574-7.
26. Elliott RL, Blobe GC. Role of transforming growth factor β in human cancer. J Clin Oncol 2005;23:2078-93.
27. Hoosein NM, McKnight MK, Levine AE, et al. Differential sensitivity of subclasses of human colon carcinoma cell lines to the growth inhibitory effects of transforming growth factor-β1. ExpCellRes 1989;181:442-53.
28. Chakrabarty S, Tobon A, Varani J, Brattain MG. Induction of carcinoembryonic antigen secretion and modulation of protein secretion/expression and fibronectin/laminin expression in human colon carcinoma cells by transforming growth factor-β. Cancer Res 1988;48:4059-64.
29. Han SU, Kwak TH, Her KH, et al. CEACAM5 and CEACAM6 are major target genes for Smad3-mediated TGF-β signaling. Oncogene 2008;27:675-83.
30. Li Y, Kumar KG, Tang W, Spiegelman VS, Fuchs SY. Negative regulation of prolactin receptor stability and signaling mediated by SCF (β-TrCP) E3 ubiquitin ligase. Mol Cell Biol 2004;24:4038-48.
31. Wysocka J, Reilly PT, Herr W. Loss of HCF-1-chromatin association precede temperature-induced growth arrest of tsBN67 cells. Mol Cell Biol 2001;21:3820-9.
32. Li F, Adam L, Vadlamudi RK, et al. p21-activated kinase 1 interacts with and phosphorylates histone H3 in breast cancer cells. EMBO Rep 2002;3:767-73. (Pubitemid 34966016)
33. Jessup JM, Petrick AT, Toth CA, et al. Carcinoembryonic antigen: enhancement of liver colonisation through retention of human colorectal carcinoma cells. Br J Cancer 1993;67:464-70.
34. Fournes B, Sadekova S, Turbide C, Letourneau S, Beauchemin N. The CEACAM1-L Ser503 residue is crucial for inhibition of colon cancer cell tumorigenicity. Oncogene 2001;20:219-30. (Pubitemid 32150267)
35. Huber M, Izzi L, Grondin P, et al. The carboxyl-terminal region of biliary glycoprotein controls its tyrosine phosphorylation and association with protein-tyrosine phosphatases SHP-1 and SHP-2 in epithelial cells. J Biol Chem 1999;274:335-44. (Pubitemid 29035067)
36. Luo W, Wood CG, Earley K, Hung MC, Lin SH. Suppression of tumorigenicity of breast cancer cells by an epithelial cell adhesion molecule (C-CAM1): the adhesion and growth suppression are mediated by different domains. Oncogene 1997;14:1697-704. (Pubitemid 27198942)
37. 1 integrin for the biological effects of GPI-anchored human carcinoembryonic antigen (CEA). J Cell Physiol 2007;211:791-802.
38. 1- fibronectin interaction. J Cell Physiol 2007;210:757-65.
39. Laguinge LM, Samara RN, Wang W, et al. DR5 receptor mediates anoikis in human colorectal carcinoma cell lines. Cancer Res 2008;68:909-17. (Pubitemid 351206770)
40. Derynck R, Akhurst RJ. Differentiation plasticity regulated by TGF-β family proteins in development and disease. Nat Cell Biol 2007;9:1000-4. (Pubitemid 47338137)
41. Pardali K, Moustakas A. Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 2007;1775:21-62. (Pubitemid 44881193)
42. van der Bij GJ, Oosterling SJ, Meijer S, Beelen RH, van Egmond M. Therapeutic potential of Kupffer cells in prevention of liver metastases outgrowth. Immunobiology 2005;210:259-65. (Pubitemid 41025167)
43. Kossmann T, Manthey CL, Brandes ME, et al. Kupffer cells express type I TGF-β receptors, migrate to TGF-β and participate in streptococcal cell wall induced hepatic granuloma formation. Growth Factors 1992;7:73-83.
44. Shibata S, Raubitschek A, Leong L, et al. A phase I study of a combination of yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody and gemcitabine in patients with CEA-producing advanced malignancies. Clin Cancer Res 2009;15:2935-41.
45. Lutterbuese R, Raum T, Kischel R, et al. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. J Immunother 2009;32:341-52.
46. Blumenthal RD, Hansen HJ, Goldenberg DM. In vitro and in vivo anti-cancer efficacy of unconjugated humanized anti-CEA monoclonal antibodies. Br J Cancer 2008;99:837-8; author reply 839-40.
47. Govindan SV, Cardillo TM, Moon SJ, Hansen HJ, Goldenberg DM. CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clin Cancer Res 2009;15:6052-61.